New CAR t combo takes on tough leukemia
NCT ID NCT04010877
First seen May 03, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This early-phase trial tests a combination of CAR T cells designed to attack different targets on leukemia cells in patients with relapsed or hard-to-treat acute myeloid leukemia. About 10 participants aged 6 months and older will receive the therapy to see if it is safe and can shrink or eliminate the cancer. The goal is to control the disease, not necessarily cure it, as ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Conditions
Explore the condition pages connected to this study.